Kyverna Therapeutics Inc.
KYTX | NASDAQ
$7.12
-$0.01 (-0.14%)
At close: Sep 21, 2026, 4:00 PM ET
$7.20
+$0.08 (+1.12%)
Pre-market:
Sep 22, 2026, 8:15 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 282K |
Cost of Revenue | n/a | 351K | n/a | n/a | 515K | 501K | 563K | 29.19M | n/a | 22.48K | 17.16M | n/a | n/a | n/a | 374K |
Gross Profit | n/a | -351K | n/a | n/a | -515K | -501K | -563K | -29.19M | n/a | -22.48K | -17.16M | n/a | n/a | n/a | -92K |
Operating Income | -39.56M | -41.37M | -39.28M | -38.73M | -44.41M | -47.41M | -41.04M | -38.77M | -33.44M | -29.36K | -21.38M | -16.28M | -13.3M | -11.45M | -8.78M |
Interest Income | 1.93M | 2.33M | 1.91M | 2M | 2.36M | 2.83M | 3.58M | 4.36M | 4.69M | 2.74M | 789K | 880K | 264K | 349K | 297K |
Pretax Income | -38.32M | -39.73M | -37.8M | -36.79M | -42.08M | -44.64M | -37.49M | -34.49M | -28.8M | -26.69K | -20.67M | -15.47M | -13.09M | -11.14M | -8.5M |
Net Income | -38.32M | -39.73M | -37.8M | -36.79M | -42.08M | -44.64M | -37.49M | -34.49M | -28.8M | -26.69K | -20.67M | -15.47M | -13.09M | -11.14M | -8.5M |
Selling & General & Admin | 14.77M | 11.29M | 9.27M | 8.27M | 8.59M | 9.98M | 7.56M | 7.88M | 6.11M | 5.78K | 4.21M | 2.64M | 2.9M | 2.73M | 1.99M |
Research & Development | 24.79M | 29.72M | 30.01M | 30.46M | 35.82M | 37.43M | 32.92M | 29.19M | 27.32M | 22.48K | 17.16M | 13.64M | 10.41M | 8.71M | 6.69M |
Other Expenses | n/a | n/a | n/a | n/a | -515K | -501K | n/a | -27.49M | n/a | -21.38K | -17.16M | n/a | n/a | n/a | n/a |
Operating Expenses | 39.56M | 41.02M | 39.28M | 38.73M | 43.9M | 46.91M | 40.48M | 9.58M | 33.44M | 6.88K | 4.21M | 16.28M | 13.3M | 11.45M | 8.68M |
Interest Expense | 674K | 667K | 444K | 7K | 14K | 25K | 27K | 32K | 39K | 44K | 47K | 50K | 46K | 44K | 41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 39.56M | 41.37M | 39.28M | 38.73M | 44.41M | 47.41M | 41.04M | 38.77M | 33.44M | 29.36K | 21.38M | 16.28M | 13.3M | 11.45M | 9.06M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 60.9M | 60.43M | 47.16M | 43.42M | 43.23M | 43.22M | 43.21M | 43.16M | 43.13M | 23.75M | 43.12M | 43.12M | 43.12M | 25.8M | 43.12M |
Shares Outstanding (Diluted) | 60.9M | 60.43M | 47.16M | 43.42M | 43.23M | 43.22M | 43.21M | 43.16M | 43.13M | 23.75M | 43.12M | 43.12M | 43.12M | 25.8M | 43.12M |
EPS (Basic) | -0.63 | -0.66 | -0.80 | -0.85 | -0.97 | -1.03 | -0.87 | -0.80 | -0.67 | -1.12 | -0.48 | -0.36 | -0.30 | -0.43 | -0.20 |
EPS (Diluted) | -0.63 | -0.66 | -0.80 | -0.85 | -0.97 | -1.03 | -0.87 | -0.80 | -0.67 | -1.12 | -0.48 | -0.36 | -0.30 | -0.43 | -0.20 |
EBITDA | -37.35M | -38.71M | -36.99M | -36.37M | -41.55M | -44.11M | -36.9M | -36.75M | -28.23M | -28.01K | -20.39M | -14.98M | -12.63M | -10.71M | -8.08M |
EBIT | -37.65M | -39.06M | -37.36M | -36.78M | -42.07M | -44.61M | -37.46M | -37.07M | -28.76M | -28.26K | -20.62M | -15.42M | -13.05M | -11.1M | -8.46M |
Depreciation & Amortization | 300K | 351K | 368K | 415K | 515K | 501K | 563K | 321K | 530K | 245 | 231K | 438K | 413K | 394K | 374K |
Add to Watchlist
Select watchlists to add or remove KYTX